Research
Hormonal
Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.
Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.
StrongSupportsmedium confidence
Despite the extended treatment gap, the patient was directed to reinitiate semaglutide at the target dose... which was followed by recurrent, symptomatic nausea and vomiting requiring medical intervention.
Why this rating
The case report provides a clear example of an adverse drug event.
Source
Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report
Olivia Denny et al. · Journal of Pharmacy Practice · 2024
DOI 10.1177/08971900241256775
case_studyCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →